Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Have Declined Over Five Years, Contributing to Shareholders 16% Loss
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Truist Financial
Jazz Pharmaceuticals Says Gastric Cancer Therapy Shows Promise in Mid-Stage Study
Express News | Jazz Pharmaceuticals PLC - Zanidatamab Plus Chemotherapy Shows Manageable Safety Profile
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Stifel Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $230
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $154
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $205
Needham Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Somewhat Strained Balance Sheet
Express News | Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Jazz Pharmaceuticals Analyst Ratings
Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress
50 Stocks to Invest During the Bull Steepening – Part 2
Russell Companies With the Lowest Tax Rates Expected to Generate $1B in 2025 – GS
Wells Fargo Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Maintains Target Price $120
Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes With Epidiolex/Epidyolex (Cannabidiol) at the European Epilepsy Congress 2024
Jazz Pharmaceuticals Plc (JAZZ): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Express News | Jazz Pharmaceuticals Shares Down 4% After $850 Mln Convertible Debt Deal Plans